Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2015

01.12.2015 | Original Article

Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer—Population-Based Analysis with Propensity Score Matching

verfasst von: Yu Jin Lim, Kyubo Kim, Eui Kyu Chie, BoKyong Kim, Sung W. Ha

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

This population-based study evaluated the survival impact of postoperative radiotherapy (PORT) in left-sided pancreatic cancer. The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with surgically resected left-sided pancreatic adenocarcinoma from 2004 to 2010. Propensity score matching was conducted to compare PORT and non-PORT groups. A total of 445 patients were identified, and PORT was performed in 180 (40 %) patients. In the unmatched population, there were no significant differences in overall survival (OS) (P = 0.197) and cause-specific survival (CSS) (P = 0.379) between the PORT and non-PORT groups. After propensity score matching, the patients treated with PORT had longer median OS (P = 0.012) and CSS (P = 0.039) than the non-PORT group. In propensity-adjusted multivariate analysis, non-receipt of PORT was a poor prognostic factor in OS (hazard ratio [HR] 1.39, 95 % confidence interval [CI] 1.08–1.79), and CSS (HR 1.31, 95 % CI 1.01–1.71). The log odds of positive lymph nodes (LOODS) (≥−0.73) was also associated with worse OS (P = 0.003) and CSS (P = 0.001). In left-sided pancreatic cancer, considering the addition of PORT is a reasonable option as in pancreatic head cancer. The LOODS was suggested as a strong predictive indicator of the patients’ prognoses.
Literatur
1.
2.
Zurück zum Zitat Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28.CrossRefPubMed Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28.CrossRefPubMed
3.
Zurück zum Zitat Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer 2007;110:2191-201.CrossRefPubMed Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer 2007;110:2191-201.CrossRefPubMed
4.
Zurück zum Zitat Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922-7.CrossRefPubMed Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922-7.CrossRefPubMed
5.
Zurück zum Zitat Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman JM. Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol 2010;17:3112-9.PubMedCentralCrossRefPubMed Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman JM. Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol 2010;17:3112-9.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, Schmidt CM, Nakeeb A, Matos JM, Scoggins CR, Martin RC, Kim HJ, Ahmad SA, Chu CK, McClaine R, Bednarski BK, Staley CA, Sharp K, Parikh AA. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg 2009;208:829-38; discussion 38-41.PubMedCentralCrossRefPubMed Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, Schmidt CM, Nakeeb A, Matos JM, Scoggins CR, Martin RC, Kim HJ, Ahmad SA, Chu CK, McClaine R, Bednarski BK, Staley CA, Sharp K, Parikh AA. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg 2009;208:829-38; discussion 38-41.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Mattiucci GC, Ippolito E, D’Agostino GR, Alfieri S, Antinori A, Crucitti A, Balducci M, Deodato F, Luzi S, Macchia G, Smaniotto D, Morganti AG, Valentini V. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:423-9.CrossRefPubMed Mattiucci GC, Ippolito E, D’Agostino GR, Alfieri S, Antinori A, Crucitti A, Balducci M, Deodato F, Luzi S, Macchia G, Smaniotto D, Morganti AG, Valentini V. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:423-9.CrossRefPubMed
8.
Zurück zum Zitat Czito BG, Willett CG. Adjuvant radiation therapy for distal pancreatic cancer: is there a role? Ann Surg Oncol 2010;17:3082-4.CrossRefPubMed Czito BG, Willett CG. Adjuvant radiation therapy for distal pancreatic cancer: is there a role? Ann Surg Oncol 2010;17:3082-4.CrossRefPubMed
9.
Zurück zum Zitat Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82.PubMedCentralCrossRefPubMed Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-90.PubMedCentralCrossRefPubMed Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-90.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat McDade TP, Hill JS, Simons JP, Piperdi B, Ng SC, Zhou Z, Kadish SP, Fitzgerald TJ, Tseng JF. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer 2010;116:3257-66.CrossRefPubMed McDade TP, Hill JS, Simons JP, Piperdi B, Ng SC, Zhou Z, Kadish SP, Fitzgerald TJ, Tseng JF. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer 2010;116:3257-66.CrossRefPubMed
12.
Zurück zum Zitat Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 2014;120:1171-7.CrossRefPubMed Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 2014;120:1171-7.CrossRefPubMed
13.
Zurück zum Zitat Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol 2014;110:960-6.CrossRefPubMed Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol 2014;110:960-6.CrossRefPubMed
14.
Zurück zum Zitat Bergenfeldt M, Moesgaard F, Burcharth F. Curative resection for left-sided pancreatic malignancy. HPB (Oxford) 2006;8:211-5.CrossRef Bergenfeldt M, Moesgaard F, Burcharth F. Curative resection for left-sided pancreatic malignancy. HPB (Oxford) 2006;8:211-5.CrossRef
15.
Zurück zum Zitat Yamamoto J, Saiura A, Koga R, Seki M, Katori M, Kato Y, Sakamoto Y, Kokudo N, Yamaguchi T. Improved survival of left-sided pancreas cancer after surgery. Jpn J Clin Oncol 2010;40:530-6.CrossRefPubMed Yamamoto J, Saiura A, Koga R, Seki M, Katori M, Kato Y, Sakamoto Y, Kokudo N, Yamaguchi T. Improved survival of left-sided pancreas cancer after surgery. Jpn J Clin Oncol 2010;40:530-6.CrossRefPubMed
16.
Zurück zum Zitat Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.CrossRef Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.CrossRef
17.
Zurück zum Zitat Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8.
18.
Zurück zum Zitat Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011;46:399-424.CrossRef Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011;46:399-424.CrossRef
19.
Zurück zum Zitat Ling Q, Xu X, Zheng SS, Kalthoff H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int 2013;12:480-7.CrossRefPubMed Ling Q, Xu X, Zheng SS, Kalthoff H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int 2013;12:480-7.CrossRefPubMed
20.
Zurück zum Zitat Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.CrossRefPubMed Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.CrossRefPubMed
21.
Zurück zum Zitat Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.CrossRefPubMed Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.CrossRefPubMed
22.
Zurück zum Zitat Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015;47:274-81.PubMedCentralCrossRefPubMed Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015;47:274-81.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW, 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;90:911-7.CrossRefPubMed Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW, 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;90:911-7.CrossRefPubMed
24.
Zurück zum Zitat Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9.PubMedCentralCrossRefPubMed Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.CrossRefPubMed Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.CrossRefPubMed
26.
Zurück zum Zitat Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.CrossRefPubMed Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.CrossRefPubMed
27.
Zurück zum Zitat La Torre M, Cavallini M, Ramacciato G, Cosenza G, Rossi Del Monte S, Nigri G, Ferri M, Mercantini P, Ziparo V. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. J Surg Oncol 2011;104:629-33.CrossRefPubMed La Torre M, Cavallini M, Ramacciato G, Cosenza G, Rossi Del Monte S, Nigri G, Ferri M, Mercantini P, Ziparo V. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. J Surg Oncol 2011;104:629-33.CrossRefPubMed
28.
Zurück zum Zitat Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:1929-35.CrossRefPubMed Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:1929-35.CrossRefPubMed
29.
Zurück zum Zitat Sun Z, Xu Y, Li de M, Wang ZN, Zhu GL, Huang BJ, Li K, Xu HM. Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer 2010;116:2571-80. Sun Z, Xu Y, Li de M, Wang ZN, Zhu GL, Huang BJ, Li K, Xu HM. Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer 2010;116:2571-80.
30.
Zurück zum Zitat Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43:121-37.CrossRef Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43:121-37.CrossRef
31.
Zurück zum Zitat La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, Balducci G, Ziparo V, Ramacciato G. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Pancreatology 2014;14:289-94.CrossRefPubMed La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, Balducci G, Ziparo V, Ramacciato G. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Pancreatology 2014;14:289-94.CrossRefPubMed
Metadaten
Titel
Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer—Population-Based Analysis with Propensity Score Matching
verfasst von
Yu Jin Lim
Kyubo Kim
Eui Kyu Chie
BoKyong Kim
Sung W. Ha
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2015
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2941-x

Weitere Artikel der Ausgabe 12/2015

Journal of Gastrointestinal Surgery 12/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.